Zapping the brain: can tDCS rewire schizophrenia?
NCT ID NCT05435300
First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 3 times
Summary
This study looks at whether a gentle brain stimulation technique called tDCS can change the density of synapses (connections between brain cells) in people with schizophrenia. Researchers will use special PET scans to measure these changes in 20 participants. The goal is to understand how tDCS works in the brain, not to treat symptoms directly.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- transcranial direct current stimulation (tDCS)
- What this could lead to
- If successful, this could reveal how tDCS affects brain connections, pointing toward better treatments for schizophrenia.
- What could go wrong
- This is a very small, early study (20 people) focused on measuring brain changes, not on treating symptoms. Results may not lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2021
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants will have Schizophrenia/Schizoaffective Disorder and currently enrolled in the tDCS-adherence parent study (REB# 103-2018).
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Enrolment in the tDCS-adherence parent study (REB# 103-2018). The parent study inclusion criteria are: 1. Male or female participants of any race or ethnicity 2. Inpatients or outpatients ≥18 years of age 3. DSM-V diagnosis of schizophrenia or schizoaffective disorder 4. Capable of consenting to participate in the research study 5. On a stable dose of oral antipsychotic drug and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study. Exclusion Criteria: The exclusion criteria for this study will be the same as the parent study (REB 103-2018). The parent study exclusion criteria are: 1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence 2. Unstable medical or any concomitant major medical or neurological illness, including a history of seizures 3. Acute suicidal or homicidal ideation 4. Formal thought disorder rating ≥3 on the Positive and Negative Syndrome Scale (PANSS) P2 conceptual disorganization item 5. DSM-V substance dependence (except caffeine, nicotine, and cannabis/marijuana) within 1 month of entering the study 6. Positive urine drug screen except for cannabis/marijuana at the screening visit 7. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia) 8. Pregnancy 9. Score \<32 on the Wide Range Achievement Test-III Additional exclusion criteria for this companion study are: 1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence 2. Exposure to long-acting injectable antipsychotics in the last 6 months 3. Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines 4. Receiving treatment with medications such as levetiracetam that blocks SV2a binding 5. Disorders of coagulation or taking anticoagulant medication 6. Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizoaffective are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
Toronto, Ontario, M5T 1R8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia